Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use
This perspective summarizes available evidence on biomarkers of exposure in electronic nicotine delivery system (ENDS) users to aid the overall assessment of the health consequences of using ENDS. Identification of novel biomarkers of exposure specific to ENDS use remains challenging because chemica...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Addiction Neuroscience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772392523000172 |
| _version_ | 1827968055753310208 |
|---|---|
| author | Maciej L. Goniewicz |
| author_facet | Maciej L. Goniewicz |
| author_sort | Maciej L. Goniewicz |
| collection | DOAJ |
| description | This perspective summarizes available evidence on biomarkers of exposure in electronic nicotine delivery system (ENDS) users to aid the overall assessment of the health consequences of using ENDS. Identification of novel biomarkers of exposure specific to ENDS use remains challenging because chemicals emitted from ENDS devices have many familiar sources. The biomarker levels of many tobacco-related toxicants measured in biological samples collected from ENDS users did not differ significantly from non-users, except for nicotine metabolites and a small number of biomarkers of exposure to volatile organic compounds and tobacco-specific tobacco nitrosamines. Several studies have shown that while exposed to nicotine, long-term exclusive ENDS users showed significantly lower levels of toxicant biomarkers than cigarette smokers. Studies have also shown that concurrent users of ENDS and combustible cigarettes (‘dual users’) are not reducing overall exposure to harmful toxicants compared to exclusive cigarette smokers. Because of an absence of validated ENDS-specific biomarkers, we recommend combining several biomarkers to differentiate tobacco product user groups in population-based studies and monitor ENDS compliance in randomized controlled trials. Using a panel of biomarkers would provide a better understanding of health effects related to ENDS use. |
| first_indexed | 2024-04-09T18:15:16Z |
| format | Article |
| id | doaj.art-118f0c5d366d4fcc8bb75e3138bb1655 |
| institution | Directory Open Access Journal |
| issn | 2772-3925 |
| language | English |
| last_indexed | 2024-04-09T18:15:16Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Addiction Neuroscience |
| spelling | doaj.art-118f0c5d366d4fcc8bb75e3138bb16552023-04-13T04:27:31ZengElsevierAddiction Neuroscience2772-39252023-06-016100077Biomarkers of Electronic Nicotine Delivery Systems (ENDS) useMaciej L. Goniewicz0Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Elam and Carlton Streets, Buffalo NY 14226, United StatesThis perspective summarizes available evidence on biomarkers of exposure in electronic nicotine delivery system (ENDS) users to aid the overall assessment of the health consequences of using ENDS. Identification of novel biomarkers of exposure specific to ENDS use remains challenging because chemicals emitted from ENDS devices have many familiar sources. The biomarker levels of many tobacco-related toxicants measured in biological samples collected from ENDS users did not differ significantly from non-users, except for nicotine metabolites and a small number of biomarkers of exposure to volatile organic compounds and tobacco-specific tobacco nitrosamines. Several studies have shown that while exposed to nicotine, long-term exclusive ENDS users showed significantly lower levels of toxicant biomarkers than cigarette smokers. Studies have also shown that concurrent users of ENDS and combustible cigarettes (‘dual users’) are not reducing overall exposure to harmful toxicants compared to exclusive cigarette smokers. Because of an absence of validated ENDS-specific biomarkers, we recommend combining several biomarkers to differentiate tobacco product user groups in population-based studies and monitor ENDS compliance in randomized controlled trials. Using a panel of biomarkers would provide a better understanding of health effects related to ENDS use.http://www.sciencedirect.com/science/article/pii/S2772392523000172Electronic Nicotine Delivery SystemsENDSE-cigarettesVapingBiomarkersExposure |
| spellingShingle | Maciej L. Goniewicz Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use Addiction Neuroscience Electronic Nicotine Delivery Systems ENDS E-cigarettes Vaping Biomarkers Exposure |
| title | Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use |
| title_full | Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use |
| title_fullStr | Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use |
| title_full_unstemmed | Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use |
| title_short | Biomarkers of Electronic Nicotine Delivery Systems (ENDS) use |
| title_sort | biomarkers of electronic nicotine delivery systems ends use |
| topic | Electronic Nicotine Delivery Systems ENDS E-cigarettes Vaping Biomarkers Exposure |
| url | http://www.sciencedirect.com/science/article/pii/S2772392523000172 |
| work_keys_str_mv | AT maciejlgoniewicz biomarkersofelectronicnicotinedeliverysystemsendsuse |